CompletedEUCTR 2010-023740-32
Pharmacogenomics of Mood Stabilizer Response in Bipolarity
This summary needs review. Please check the official study record and contact the research team for details.
In NorwayBipolarityOther
Study directory
Back to overviewMental health studies with practical context.
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
CompletedNCT01272531
Pharmacogenomics of Mood Stabilizer Response in Bipolarity (PGBD)
This study exists to explore whether this type of care could improve care and understanding. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.
Multiple locations, including San DiegoBipolarityDrugA study involving a medication or substance.Over 18 Years
CompletedNCT05669391
Pharmacogenomics on Individualized Precise Treatment of people with Depression
This summary needs review. Please check the official study record and contact the research team for details.
In ShanghaiDepressionDiagnostic TestA study that looks at how to detect, measure, or better understand a condition.From 18 Years to 65 Years
TerminatedNCT03886753
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
This summary needs review. Please check the official study record and contact the research team for details.
In PhiladelphiaPTSDOtherOver 2 Years
CompletedNCT00914862
Pharmacokinetic and Safety of Ramelteon Between Adolescents With Insomnia and Healthy Adults
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Overland ParkADHDDrugFrom 6 Years to 50 Years
CompletedNCT02055287
Pharmacokinetic and Safety Study of LY03004 in Stable people with Schizophrenia or Schizoaffective Disorder
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including OrangeSchizophreniaDrugFrom 18 Years to 65 Years
CompletedNCT03006367
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
This study exists to better understand the safety of the medication NFC-1 and how manageable it feels in practice. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.
Multiple locations, including MaitlandADHDDrugFrom 6 Years to 17 Years
CompletedNCT02260830
Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167
This summary needs review. Please check the official study record and contact the research team for details.
In NottinghamSchizophreniaDrugFrom 18 Years to 45 Years
TerminatedNCT04468360
Pharmacokinetic Study for IV Allopregnanolone
This summary needs review. Please check the official study record and contact the research team for details.
In BostonPTSDDrugFrom 18 Years to 55 Years
CompletedNCT02578030
Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
This study exists to explore whether this type of care could improve care and understanding. For people living with ADHD, that matters because care needs to work in daily life, not just in theory.
Multiple locations, including MiamiADHDDrugFrom 6 Years to 17 Years
CompletedNCT01043458
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including GlendaleSchizophreniaDrugFrom 18 Years to 55 Years
CompletedNCT03610464
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
This study exists to explore whether the medication DYANAVEL could improve care and understanding. Researchers are trying to understand whether the medication DYANAVEL can improve attention, thinking, or day-to-day functioning.
In MaitlandADHDDrugFrom 4 Years to 5 Years
Public registry coverage is progressing
HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.